Mazyar Shadman, MD
Hematology & Oncology · Seattle, WANPI 1750554077
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $196,107 of the $225,888 with a category attached, or 86.8%. It is spread thinly across 35 manufacturers, the largest accounting for just 12.5%. Among hematology & oncology clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 254 payments — averaging $889.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$28K
- ADC Therapeutics America, Inc.$26K
- E.r. Squibb & Sons, L.L.C.$24K
- AstraZeneca$17K
- Genentech USA, Inc.$14K
- Genentech, Inc.$9K
- plus $107K from 29 others
Across 989 payments — averaging $36,978 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Beigene, Ltd.$25.8M
- AstraZeneca$3.6M
- Beone Medicines Ltd.$2.8M
- Bristol Myers Squibb$1.3M
- Genentech, Inc.$1.2M
- Astrazeneca UK Limited$505K
- plus $1.3M from 12 others
What the payments were for
- Consulting fees$196,10787%
- Speaking & faculty fees$14,1426%
- Travel & lodging$6,0323%
- Food & beverage$9,5864%
- Education$210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 49 | $28,320 |
| ADC Therapeutics America, Inc. | 23 | $26,088 |
| E.r. Squibb & Sons, L.L.C. | 9 | $24,060 |
| AstraZeneca | 24 | $16,960 |
| Genentech USA, Inc. | 14 | $13,872 |
| Genentech, Inc. | 14 | $9,432 |
| Beigene USA, Inc. | 14 | $9,323 |
| Merck | 2 | $9,269 |
| Lilly USA, LLC | 4 | $9,256 |
| Gilead(2 entities) | 4 | $7,800 |
| Janssen Global Services, LLC | 4 | $6,300 |
| Pfizer | 6 | $5,950 |
| Pharmacyclics LLC, An Abbvie Company | 12 | $5,060 |
| Morphosys AG | 4 | $4,833 |
| Genmab U.S., Inc. | 6 | $4,482 |
| F. Hoffmann-la Roche AG | 13 | $4,348 |
| Johnson & Johnson | 4 | $4,155 |
| Eli Lilly | 6 | $3,879 |
| Pierre Fabre Pharmaceuticals, Inc. | 3 | $3,866 |
| Beigene Switzerland GmbH | 4 | $3,602 |
| Regeneron | 2 | $3,275 |
| Beigene, Ltd. | 2 | $3,250 |
| Beone Medicines USA, Inc. | 7 | $3,141 |
| Astrazeneca UK Limited | 2 | $2,774 |
| Incyte Corporation | 3 | $2,515 |
| Bristol Myers Squibb | 6 | $2,445 |
| Innate Pharma, Inc | 1 | $2,400 |
| Epizyme, Inc. | 2 | $2,037 |
| Adaptive Biotechnologies Corporation | 1 | $1,500 |
| Janssen Scientific Affairs, LLC | 1 | $1,010 |
| Seagen Inc. | 2 | $288 |
| Edwards Lifesciences | 1 | $150 |
| Taiho Oncology, Inc. | 3 | $115 |
| TG Therapeutics, Inc. | 1 | $106 |
| Morphosys, US Inc. | 1 | $28 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$225,888 in reported general payments places this provider in the 95th percentile of 349 hematology & oncology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 21 | $298,838 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Beigene USA, Inc.Brukinsa | $9,323 | $298,83821 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 349 hematology & oncology providers in Washington.
Other hematology & oncology in Seattle
- John PesandoSeattle$15.7M
- Jill JohnsenSeattle$991K
- Fengting YanSeattle$841K
- John PagelSeattle$725K
- Lawrence FongSeattle$546K
- Langdon MillerSeattle$457K
- Catherine LeeSeattle$199K
- Celestia HiganoSeattle$164K
- Ryan CassadaySeattle$151K
- Rebecca Kruse-JarresSeattle$140K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.